首页 美制药(usMEIP)-基本信息

美制药(usMEIP)-基本信息

日报更新时间:07-02 06:53

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:美制药


英文名称:MEI Pharma


简介:MEI Pharma, Inc.,是一家处于发展阶段的抗肿瘤公司,专注于针对癌症的新型疗法的临床开发


电话:1-858-3697100,1-858-7926300


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2018-08-06 Urso David M Chief Operating Officer Sell 9500 3.58
2018-08-05 Gold (Daniel P) Officer and Director Sell 50938 3.75
2018-08-05 Mass (Robert D) Officer Sell 17709 3.75
2018-08-05 Urso David M Chief Operating Officer Sell 17764 3.75
2018-03-28 Gold (Daniel P) Chief Executive Officer Sell 128920 2.07
2017-11-26 Baltic (Charles V III) Director Sell 11000 2.21
2017-11-26 Baltic (Charles V III) Director Buy 11000 2.25

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Bailard Inc 503292 0.71% 122000 32.00% 2019-03-31
Sio Capital Management, LLC 2356633 3.31% -17208 -0.72% 2019-03-31
Vanguard Group Inc 2504623 3.51% 99706 4.15% 2019-03-31
Bvf Inc 2698755 3.79% -279953 -9.40% 2019-03-31
Boxer Capital LLC 2913091 4.09% -- -- 2019-03-31
Caxton Corp 3459124 4.85% -- -- 2019-03-31
Perceptive Advisors LLC 4400440 6.17% -- -- 2019-03-31
NEA Management Company, LLC 5720572 8.02% -- -- 2019-03-31
Vivo Capital, LLC 5778106 8.11% -- -- 2019-03-31
BlackRock Fund Advisors 2298191 3.22% 2915 0.13% 2019-07-31
Renaissance Technologies Corp 2125013 2.98% -198700 -8.55% 2019-03-31
Vanguard Investments Australia Ltd 1982270 2.78% -- -- 2019-07-31
Candriam Belgium 510000 0.72% -- -- 2019-07-31
Candriam Luxembourg S.C.A. 510000 0.72% -- -- 2019-03-31
BlackRock Inc 597167 0.84% 8534 1.45% 2019-03-31
Delaware Management Company 600000 0.84% -- -- 2019-07-31
Macquarie Group Ltd 600000 0.84% -- -- 2019-03-31
Indus Capital Partners, LLC 631513 0.89% -- -- 2019-03-31
Millennium Management LLC 693133 0.97% 491548 243.84% 2019-03-31
Wasatch Advisors Inc. 1109571 1.56% 380531 52.20% 2019-03-31
Fosun International Ltd 396526 0.56% -- -- 2019-03-31
Geode Capital Management, LLC 522556 0.73% 282013 117.24% 2018-12-31
Candriam Luxembourg 510000 0.72% -- -- 2019-03-31
Hauck & Aufh 396526 0.56% -- -- 2019-04-30
Dimensional Fund Advisors, Inc. 388266 0.55% -57432 -12.89% 2018-12-31
Connor Clark & Lunn Inv Mgmt Ltd 355614 0.50% 4089 1.16% 2018-09-30
EAM Investors, LLC 373889 0.53% 536 0.14% 2018-09-30
Opus Point Partners Management, LLC 360000 0.51% -40000 -10.00% 2018-09-30
Walleye Trading LLC 449443 0.63% 342501 320.27% 2018-06-30
BlackRock Institutional Trust Company NA 387993 0.55% -- -- 2018-06-30
J.P. Morgan Securities Inc 366819 0.52% 366819 -- 2018-06-30
ARONSON+JOHNSON+ORTIZ 438710 0.62% 337759 334.58% 2018-03-31
JPMorgan Chase & Co 366819 0.52% 366819 -- 2018-06-30
Fidelity Management & Research Company 435059 0.61% -184749 -29.81% 2018-10-31
EAM Investors 373353 0.53% 373353 -- 2018-06-30
Longwood Capital Partners LLC 880087 1.25% 880087 -- 2018-06-30
Renaissance Technologies LLC 2014113 5.45% 2014113 -- 2017-09-08
Vivo Opportunity, LLC 6600660 17.69% 6600660 -- 2018-05-11
New Enterprise Associates 16, LP 7025641 9.99% 7025641 -- 2018-05-16
Medical Strategy GmbH 319526 0.45% 123049 62.63% 2018-06-30
Clarivest Asset Management LLC 206600 0.55% 4900 2.43% 2018-03-31
Oxford Asset Management, LLC 226980 0.61% -104098 -31.44% 2018-03-31
TFS Capital LLC 167442 0.46% 66328 65.60% 2017-07-31
Apo Asset Management GmbH 197625 0.28% 43901 28.56% 2018-07-31
Jacobs Levy Equity Management, Inc. 183447 0.49% -6500 -3.42% 2018-03-31
Deutsche Bank AG 180213 0.48% -47719 -20.94% 2018-03-31
Acadian Asset Management LLC 122259 0.33% -27054 -18.12% 2018-03-31
Ancora Advisors LLC 167462 0.45% -- -- 2018-03-31
Algert Global LLC 100140 0.27% -133754 -57.19% 2018-03-31
Northern Trust Investments N A 73404 0.20% -- -- 2017-12-31
Morgan Stanley Smith Barney LLC 76100 0.21% -174900 -69.68% 2017-12-31
Ad Valorem Research S.L. 69874 0.19% -412 -0.59% 2017-06-30
Anson Funds Management LP 486969 1.32% 486969 -- 2016-12-31
Macquarie Investment Management Limited 96170 0.26% -18055 -15.81% 2017-12-31
Spark Investment Management LLC 60700 0.16% -1800 -2.88% 2017-09-30
Two Sigma Investments LLC 87583 0.24% 87583 -- 2017-09-30
Nationwide Fund Advisors 85500 0.23% 85500 -- 2017-09-30
Helsinn Investment Fund SA 2616431 7.66% 2616431 -- 2016-08-16
Vivo Ventures VII LLC 2458995 7.20% 2458995 -- 2016-04-06
Bridgeway Capital Management, Inc 427500 1.16% -- -- 2016-09-30
Iguana Healthcare Management, LLC 300000 0.82% 300000 -- 2016-09-30
Goodwood Advisors, LLC 150000 0.41% -- -- 2016-12-31
Vivo Ventures V, LLC 142861 0.42% 142861 -- 2016-04-06
Victory Capital Management Inc. 57642 0.16% -- -- 2016-09-30
Goldman, Sachs & Co. 51429 0.14% 28330 122.65% 2016-09-30
Connor Clark & Lunn Financial Group 58675 0.16% -- -- 2017-01-31
Technical Financial Services LLC 40382 0.11% 40382 -- 2016-09-30
Frigate Ventures LP 1715000 10.00% 2744000 -- 1999-11-30
Vivo Ventures Funds, LLC 3760136 10.00% 6016218 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Alumot Equities Top Ideas 200000 0.28% 200000 -- 2019-05-31
MEDICAL BioHealth 396526 0.56% -- -- 2019-04-30
Vanguard Extended Market Index Fund 397761 0.56% -- -- 2019-06-30
Candriam Eqs L Biotechnology 510000 0.72% -- -- 2019-06-30
Delaware Healthcare Fund 600000 0.84% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 617710 0.87% -- -- 2019-07-30
Wasatch Ultra Growth Fund 1280035 1.80% 175935 15.93% 2019-06-30
iShares Russell 2000 ETF 1486878 2.09% 2915 0.20% 2019-07-30
Vanguard Total Stock Market Index Fund 1982270 2.78% -- -- 2019-06-30
BlackRock Russell 2500 91822 0.13% 91822 -- 2019-06-30
APO Medical Opportunities 220157 0.31% -- -- 2019-06-30
Nationwide Bailard Tech&Sci Fund 107792 0.15% -- -- 2019-06-30
iShares Micro-Cap ETF 173834 0.24% -- -- 2019-07-30
Fidelity 153139 0.21% -- -- 2019-06-30
Schwab Small Cap Index Fund 141679 0.20% 141679 -- 2019-06-30
Russell 2000 Index Non-Lendable Fund E 129193 0.18% 129193 -- 2019-06-30
The Vanguard - Russell 2000 Grwth Idx CF 128041 0.18% 128041 -- 2019-06-30
Vanguard Balanced Index Fund 93726 0.13% 80600 614.05% 2019-06-30
iShares Russell 2000 Small-Cap Index Fd 101748 0.14% 101748 -- 2019-06-30
Vanguard Instl Total Stock Market Idx Fd 95949 0.13% -- -- 2019-06-30
BlackRock Russell 2000 85437 0.12% 85437 -- 2019-06-30
DFA US Core Equity II Fund 83632 0.12% -- -- 2019-05-31
BlackRock Extended Equity Market 73428 0.10% -101 -0.14% 2019-06-30
Acuitas US Microcap Fund 56800 0.08% 9000 18.83% 2019-03-31
RIM Global Bioscience 52504 0.07% -- -- 2019-05-31
apo Medical Opportunities Institutionell 52259 0.07% -- -- 2019-05-31
DFA US Small Cap Portfolio 46324 0.06% -- -- 2019-05-31
ALPS Medical Breakthroughs ETF 170290 0.24% -- -- 2019-05-31
PHARMA/wHEALTH 44539 0.06% -- -- 2018-07-31
Variopartner SICAV - Pharma/wHealth 44539 0.06% -- -- 2018-12-31
DFA US Core Equity 1 Portfolio 37625 0.05% -- -- 2018-12-31
FCP MEDICAL BioHealth-Trends 319526 0.45% -- -- 2018-10-31
Munda Valor Investments SICAV 39917 0.06% -93 -0.23% 2018-03-31
DFA US Targeted Value Portfolio 72586 0.10% -- -- 2018-11-30
GuideStone Funds Small Cap Equity Fund 59107 0.08% 59107 -- 2018-03-31
Vanguard Global Equity Fund 49908 0.07% -10401 -17.25% 2018-03-31
FCP MEDICAL BioHealth 319526 0.45% 123049 62.63% 2018-06-30
TFS Market Neutral Fund 167442 0.24% 66328 65.60% 2017-07-31
Nationwide Bailard Cognitive Value Fund 78100 0.11% -- -- 2017-10-31
DFA US Core Equity 2 I 83632 0.12% -- -- 2018-07-31
DFA US Vector Equity I 20418 0.03% -- -- 2018-07-31
DFA Tax-Managed US Small Cap 24871 0.04% -- -- 2018-07-31
DFA US Small Cap I 25224 0.04% -- -- 2018-07-31
Russell US Small Cap Equity I 31250 0.04% -2800 -8.22% 2018-07-31
Vanguard Total Stock Mkt Idx 896606 1.27% 15800 1.79% 2018-07-31
Vanguard Extended Market Idx Inv 388861 0.55% -- -- 2018-07-31
Delaware Healthcare A 310000 0.44% 50000 19.23% 2018-07-31
Wasatch Ultra Growth 213821 0.30% 213821 -- 2018-06-30
TFS Market Neutral 167442 0.46% 66328 65.60% 2017-07-31
iShares Micro-Cap 95438 0.14% -- -- 2018-09-12
Acuitas US Microcap Institutional 75900 0.11% -15300 -16.78% 2018-06-30
BlackRock Extended Equity Market K 72929 0.10% 1983 2.80% 2018-06-30
Vanguard Balanced Index Inv 31611 0.04% -- -- 2018-07-31
DFA US Core Equity 1 I 37625 0.05% -- -- 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 61287 0.09% -- -- 2018-07-31
Fidelity Spartan 62189 0.09% -- -- 2018-07-31
Nationwide Bailard Tech&Sci M 65000 0.09% -- -- 2018-07-31
DFA US Targeted Value I 72586 0.10% -- -- 2018-07-31
Vanguard Global Equity Inv 49908 0.13% -10401 -17.25% 2018-03-31
BNY Mellon EB DL Mkt Completion 19577 0.03% -- -- 2018-06-30
iShares Core S&P Total US Stock Mkt 13889 0.02% -- -- 2018-07-12
SA US Small Company 13204 0.02% -- -- 2018-06-30
Wilshire Micro-Cap ETF 10237 0.02% -- -- 2018-07-05
GuideStone Funds Small Cap Equity Instl 59107 0.16% 59107 -- 2018-03-31
Quaker Small-Cap Value A 32836 0.09% -8200 -19.98% 2018-02-28
DFA US Small Cap Value II 19881 0.05% -- -- 2017-12-31
BNY Mellon Market Completion Fund UC1 19577 0.05% 18385 1542.37% 2017-09-30
Bridgeway Ultra-Small Company 427500 1.16% -- -- 2016-09-30
Goodwood SMID Cap Discovery A 150000 0.41% -- -- 2016-12-31
Vericimetry U.S. Small Cap Value 19100 0.05% 19100 -- 2016-09-30
The Vanguard Total Stock Market Index 13200 0.04% -- -- 2016-12-31
USAA Extended Market Index 8458 0.02% -1 -0.01% 2016-09-30
AXA/Lord Abbett Micro Cap K 5118 0.01% -- -- 2016-11-30
Master Extended Market Index Series 8459 0.02% -- -- 2016-12-31
Bridgeway Ultra Small Company Fund 390000 1.10% 192700 97.70% 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 92428 0.30% -- -- 2015-09-30
Vanguard Instl Total Stock Market Index 48787 0.10% -- -- 2015-10-31
Fidelity Spartan® Total Market Idx Fund 26819 0.10% -- -- 2015-09-30
BlackRock Extended Equity Market Fund 17981 -- 17981 -- 2015-09-30
The Vanguard - Total Stk Mkt Idx Trust. CF 13200 -- -- -- 2015-10-31
CC&L All Strategies 7500 -- 700 10.30% 2015-10-31
Fidelity® NASDAQ Composite Index® Fund 6684 -- -- -- 2015-09-30
Fidelity® Small Cap Stock Fund 617381 1.80% -246919 -28.60% 2015-07-31
Mellon Capital EB DL Mkt Completion Fund 24836 0.10% -- -- 2015-09-30

Frederick W. Driscoll Frederick W. Driscoll is on the board of NantKwest, Inc. and 4 other companies. Mr. Driscoll previously occupied the position of Chairman for Mateon Therapeutics, Inc., Chairman, President & Chief Executive Officer at Mateon Therapeutics, Inc., Chief Financial Officer at Astraris, Inc., Chief Financial Officer, Treasurer & VP at Novavax, Inc., Chief Financial Officer at Flexion Therapeutics, Inc., Senior Vice President-Finance & Operations at Collagenesis Corp., President & Chief Executive Officer of Genelabs Technologies, Inc. and Vice President-Finance-Americas & Controller at Instrumentation Laboratory Co. He received an undergraduate degree from Bentley University.
Richard G. Ghalie Presently, Richard G. Ghalie holds the position of Senior Vice President-Clinical Development at MEI Pharma, Inc. He is also on the board of Viracta Therapeutics, Inc. In his past career Dr. Ghalie held the position of VP-Clinical Research & Regulatory Affairs at Poniard Pharmaceuticals, Inc., VP-Medical Affairs & Professional Services at Ligand Pharmaceuticals, Inc., Chief Medical Officer at Denovo Biopharma, Chief Medical Officer for Novalar Pharmaceuticals, Inc., Chief Medical Officer for Favrille, Inc., Chief Medical Officer for HemaQuest Pharmaceuticals, Inc., Senior Medical Director-Oncology Products at Immunex Corp. and Medical Director-Bone Marrow Transplant Center at Rush University Medical Center. Dr. Ghalie received an MBA from the University of Washington, a doctorate from St. Joseph's College and a graduate degree from Universit�0�1�0�8 Paris Diderot-Paris 7.
Kevan E. Clemens Kevan E. Clemens is on the board of MEI Pharma, Inc. In his past career he held the position of Vice President for Specialty Care, Inc., Independent Director at Chelsea Therapeutics International Ltd., Head-Pharmacoeconomics & Pricing at de Syntex & Roche SA de CV and Executive Vice President & Business Director at Hoffmann-La Roche, Inc. Kevan E. Clemens received a doctorate from University College London.
Thomas C. Reynolds Presently, Thomas C. Reynolds is President at Two Paddles Consulting LLC. Dr. Reynolds is also on the board of Trillium Therapeutics, Inc. and MEI Pharma, Inc. In the past Dr. Reynolds occupied the position of Chief Medical Officer for Seattle Genetics, Inc., Vice President-Medical Affairs for ZymoGenetics, Inc., Vice President-Clinical Affairs at Somatix Therapy Corp. and Vice President-Clinical Affairs at AmpliPhi Biosciences Corp. He received a doctorate from Stanford University and an undergraduate degree from Dartmouth College.
Charles V. Baltic Charles V. Baltic is on the board of MEI Pharma, Inc. and SIDIS, Inc. In the past Mr. Baltic held the position of Managing Director at CRT Capital Group LLC, Managing Director-Healthcare Investment Banking at Wachovia Securities LLC, Member of US Securities & Exchange Commission and Director-Life Science at Cowen & Co. (New York). He received a graduate degree and an undergraduate degree from Georgetown University and an MBA from The Wharton School of the University of Pennsylvania.
Tamar D. Howson Ms. Tamar D. Howson is an Independent Director at Organovo Holdings, Inc. She is on the Board of Directors at MEI Pharma, Inc., Organovo Holdings, Inc., International Partnership for Microbicides and Organovo, Inc. Ms. Howson was previously employed as an Independent Director by ContraVir Pharmaceuticals, Inc., an Independent Director by Enzymotec Ltd., an Independent Director by Cynapsus Therapeutics, Inc., an Independent Director by Cardax, Inc., an Independent Director by Actavis Plc, an Independent Director by Aradigm Corp., an Independent Director by Soligenix, Inc., an Independent Director by Mateon Therapeutics, Inc., an Independent Director by Idenix Pharmaceuticals LLC, a Principal by Howson Associates Ltd., a Member by JSB-Partners LP, an Executive Vice President-Corporate Development by Lexicon Pharmaceuticals, Inc., a Senior VP-Corporate & Business Development by Bristol-Myers Squibb Co., a Senior VP & Director-Business Development by GlaxoSmithKline Plc, a Senior VP & Director-Business Development by Smithkline Beecham Plc, a Vice President-Venture Investments by Johnston Associates, Inc., a Director-Worldwide Business Development by Squibb Corp., and a Chief Executive Officer & Director by S*BIO Pte Ltd. She also served on the board at Cardax Pharmaceuticals, Inc., Warner Chilcott Plc, Worldwide Business Development Corp., ARIAD Pharmaceuticals, Inc., BioLineRx Ltd., HBA Corp., Healthcare Businesswomens Association, NPS Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc. (California), SkyePharma Plc and Targacept, Inc. She received her undergraduate degree from Technion-Israel Institute of Technology, a graduate degree from The City College of New York and an MBA from Columbia University.
Brian G. Drazba Brian G. Drazba is CFO, Secretary & Principal Accounting Officer at MEI Pharma, Inc. In the past Mr. Drazba occupied the position of Chief Financial & Accounting Officer, VP at Heron Therapeutics, Inc., Chief Accounting Officer & VP-Finance at ISTA Pharmaceuticals, Inc. and Chief Accounting Officer & Senior Vice President for InSight Health Services Holdings Corp. and Chief Accounting Officer & Senior Vice President for InSight Health Corp. (a subsidiary of InSight Health Services Holdings Corp.). Brian G. Drazba received an undergraduate degree from the University of San Diego.
Daniel P. Gold Daniel P. Gold founded Favrille, Inc. and MMRGlobal, Inc. He is President, Chief Executive Officer & Director at MEI Pharma, Inc. Dr. Gold is also on the board of The Hope Funds for Cancer Research. In his past career Dr. Gold was President & Chief Executive Officer of Prospect Therapeutics, Inc., Managing Partner at Theragence, Inc., Chief Scientific Officer of Favrille, Inc. and Associate Professor at Sidney Kimmel Cancer Center. Dr. Gold received an undergraduate degree from the University of California, Los Angeles and a doctorate from Tufts University.
Nicholas R. Glover Currently, Nicholas R. Glover is President, Chief Executive Officer & Director at Sierra Oncology, Inc. He is also on the board of MEI Pharma, Inc. In his past career Dr. Glover held the position of President, Chief Executive Officer & Director at Viventia Biotech, Inc., President, Chief Executive Officer & Director at YM BioSciences, Inc., Investment Manager at Lumira Capital Investment Management, Inc. and Investment Analyst at University Medical Discoveries, Inc. Dr. Glover received a doctorate from Simon Fraser University, an undergraduate degree from the University of East Anglia and a graduate degree from the University of British Columbia.
William Dodge Rueckert William Dodge Rueckert is a businessperson who has been the head of 10 different companies. Presently, Mr. Rueckert is President & Director at Cleveland H. Dodge Foundation, Inc. and President of Oyster Management Group LLC. He is also Co-Chairman at Teachers College (New York) and Co-Chairman of Columbia University and on the board of 9 other companies. In his past career he was Non-Executive Chairman at Novagen Ltd., Chairman & Chief Executive Officer of Kazia Therapeutics Ltd., President & Director at Eastern Capital Development LLC, President & Director at Rosow & Co., Inc., Treasurer of Moore & Munger, Inc. and President for United States Oil Co. William Dodge Rueckert received an undergraduate degree from the University of New Hampshire.
Christine Anna White Christine Anna White founded Apoptos, Inc. Currently, Dr. White is Non-Executive Chairman of MEI Pharma, Inc. In her past career Dr. White occupied the position of Senior Vice President-Global Medical Affairs at Biogen, Inc. and Vice President-Medical Affairs at IDEC Pharmaceuticals Corp. (a subsidiary of Biogen, Inc.), Director-Clinical Oncology Research at Sidney Kimmel Cancer Center and Chairman-Medicine Department at Scripps Memorial Hospital La Jolla. She received a doctorate and an undergraduate degree from The University of Chicago.
Robert D. Mass Dr. Robert D. Mass, MD, is Chief Medical Officer at MEI Pharma, Inc. Dr. Mass was previously employed as Head-Medical Affairs by Genentech, Inc. He received his undergraduate degree from Tufts University and a doctorate degree from Oregon Health Sciences University.
David A. Walsey Presently, David A. Walsey holds the position of VP-Investor Relations & Corporate Communications at MEI Pharma, Inc. Mr. Walsey previously was Vice President-Corporate communications at Alder Biopharmaceuticals, Inc., Director-Corporate Communications at Arena Pharmaceuticals, Inc., Senior Director-Investor Relations at Sarepta Therapeutics, Inc., VP-Investor Relations & Corporate Communications at Optimer Pharmaceuticals LLC and Head-Investor Relations & Corporate Communications at Maxim Pharmaceuticals, Inc. He received a graduate degree from New York University School of Law, a graduate degree from Brooklyn Law School and an undergraduate degree from Franklin & Marshall College.
David M. Urso Founder of Tioga Pharmaceuticals, Inc., David M. Urso currently is COO, SVP-Corporate Development & General Counsel at MEI Pharma, Inc. In the past Mr. Urso was COO, Director & General Counsel at Tioga Pharmaceuticals, Inc., Principal at GlaxoSmithKline Plc, Attorney at Wilson Sonsini Goodrich & Rosati PC, Director-Corporate Development & Legal Affair at DNA Sciences, Inc., Attorney at Cooley Godward LLP and Principal at the University of Pennsylvania. He received an undergraduate degree from Reed College and a graduate degree from Harvard Law School.
Karen E. Potts Karen E. Potts is Senior Vice President-Regulatory Affairs at MEI Pharma, Inc. In the past Dr. Potts held the position of Director-Regulatory Affairs at Ionis Pharmaceuticals, Inc., Associate Director-Regulatory Affairs at Pfizer Inc. Senior Research Scientist-Infectious Disease at G.D. Searle & Co. Ltd. and Senior Research Scientist-Virology at Agouron Pharmaceuticals LLC (both are subsidiaries of Pfizer Inc.), Senior Vice President-Regulatory Affairs at Trius Therapeutics, Inc. and Senior Director-Regulatory Policy at Allergan, Inc. Karen E. Potts received a doctorate from Emory University and an undergraduate degree from Smith College.
Robert D. Mass Currently, Robert D. Mass is Chief Medical Officer of MEI Pharma, Inc. Dr. Mass previously was Head-Medical Affairs at Genentech, Inc. Dr. Mass received an undergraduate degree from Tufts University and a doctorate from Oregon Health Sciences University.
Ofir Moreno Dr. Ofir Moreno is a Senior Vice President-Pharmaceutical Sciences at MEI Pharma, Inc. Dr. Moreno was previously employed as a Senior Director-Chemistry by Dendreon Corp. He received his undergraduate degree from Cornell University and a doctorate degree from Harvard University.

量化对比

全部评论 1

  • MEI Pharma(MEIP.O)盘前涨超80%,此前与医药公司协和麒麟签订药物许可协议。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐